Better diagnostics, driven by conviction
Cube Dx brings together experts from various disciplines with many years’ experience, all united by a single goal: to drastically reduce the time to diagnose severe microbial infections. Improving the accuracy of the diagnosis enables better treatment decisions to be made.
To achieve this goal, Cube Dx focuses on the development, manufacture and distribution of multiplex tests for clinical in vitro diagnostics.
Founded in 2015, Cube Dx has developed a comprehensive and entirely new multiplex technology based on the principle of microarrays. The hybcell is the first and only cylindrical microarray in the world, delivering fast and reliable results with minimal effort.
The people behind cube dx
Precision as a commitment
Precision at every stage and a commitment to quality. Only carefully developed and manufactured IVDR-compliant products deliver reliable results.
Resilience as a mission
Short supply chains, European value creation and full control over technology and production are important to us – autonomy from the initial idea right through to the finished product.
Close to the hospital
The first sepsis test was introduced in the first clinical laboratories in 2020 and has been in routine clinical use ever since – a wealth of experience on which we continue to build.
Facts not fiction
compact sequencing and hybcell technology have been used and evaluated in several independent clinical assessments and studies. As the number of customers grows, so does the number of available publications. You can find an overview in our Publications & Studies.
